Related Experiment Video
Updated: Jul 24, 2026
An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Management of giant cell arteritis and polymyalgia rheumatica
S Meskimen1, T D Cook, R L Blake
1Department of Family and Community Medicine, University of Missouri-Columbia School of Medicine, 65212, USA.
Insights
Giant cell arteritis and polymyalgia rheumatica are inflammatory conditions affecting older adults. Treatment with corticosteroids provides rapid symptom relief but often requires long-term management and can lead to complications.
Area of Science:
- Rheumatology
- Internal Medicine
- Vasculitis
Background:
- Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are common, related inflammatory disorders in individuals over 50.
- GCA presents with headache, systemic symptoms, and temporal artery tenderness, diagnosed via biopsy.
- PMR involves proximal muscle pain and stiffness, diagnosed clinically.
Purpose of the Study:
- To describe the clinical presentation, diagnosis, and management of GCA and PMR.
- To outline corticosteroid treatment strategies for both conditions.
- To highlight the long-term course and potential complications.
Main Methods:
- Review of clinical features and diagnostic criteria for GCA and PMR.
- Description of standard corticosteroid dosing for GCA and PMR.
- Discussion of treatment monitoring and tapering protocols.
Main Results:
- Both GCA and PMR are characterized by elevated erythrocyte sedimentation rate (ESR).
- Corticosteroids (prednisone) are the mainstay of treatment, with higher doses for GCA (40-60 mg/day) and lower for PMR (10-20 mg/day).
- Rapid symptom response to corticosteroids confirms diagnosis; long-term therapy (2-3 years) is often necessary, with monitoring for recurrence and complications.
Conclusions:
- GCA and PMR are distinct but related conditions requiring prompt diagnosis and management.
- Corticosteroid therapy is effective but necessitates careful monitoring due to potential long-term complications.
- Symptom relief and ESR normalization guide treatment adjustments and tapering strategies.
Abstract:
Giant cell arteritis and polymyalgia rheumatica are closely related disorders that affect persons more than 50 years of age and cause substantial morbidity. Patients with giant cell arteritis typically have a localized headache, nonspecific systemic symptoms, temporal artery tenderness and a high erythrocyte sedimentation rate (ESR). The diagnosis is confirmed by characteristic pathologic findings on temporal artery biopsy. Patients with polymyalgia rheumatica usually have similar nonspecific systemic symptoms, proximal muscle pain and stiffness, and an elevated ESR. The diagnosis is based on the clinical findings. Both disorders are treated with corticosteroids: high dosages for giant cell arteritis (prednisone in a dosage of 40 to 60 mg per day) and lower dosages for polymyalgia rheumatica (prednisone in a dosage of 10 to 20 mg per day). Symptom relief in response to treatment is rapid and reinforces the diagnosis. After normalization of the ESR, the corticosteroid is tapered, with the patient monitored closely for symptom recurrence. Most patients require corticosteroid therapy for two to three years and experience one or more treatment complications.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:14Myocarditis III: Medical Management
01:22Myocarditis IV: Nursing Management
01:17Pericarditis III: Medical Management
01:21Rheumatic Heart Disease III: Medical Management
01:20Rheumatic Heart Disease IV: Nursing Management